Status:
COMPLETED
COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients
Lead Sponsor:
Zoé van Kempen
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Patients with MS are possibly more vulnerable to infection with SARS-CoV-2. Furthermore the use of immunomodulatory treatment could have an effect on the course of COVID-19 disease. This ha...
Eligibility Criteria
Inclusion
- a current diagnosis of multiple sclerosis and age ≥18 years.
Exclusion
- lack of informed consent.
Key Trial Info
Start Date :
August 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
546 Patients enrolled
Trial Details
Trial ID
NCT04498286
Start Date
August 8 2020
End Date
October 31 2021
Last Update
January 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU medical center
Amsterdam, Netherlands